50:00 and following. Bret makes SUCH a good point here. As a clinical pharmacist, I have to review guidelines and studies frequently. Bret's specific point about (almost) fetishizing phase 3 data over "phase 4 data" is a wonderful articulation. Ivermectin, or any other drug that has been on the market for decades, will have a wealth of phase 4 data -- either a history of problems and complications with various relevancy, or no major issues. Imagine downplaying decades of feedback information just because a randomized controlled trial is a standard you prefer. Yes, RCTs play a role in medication therapy, but they are not everything nor even always the most important.